title: Reply: To PMID 23099497.
authors.affiliation: *Ophthalmology Unit, Pio del Rio Hortega University Hospital, Valladolid, Spain †VISSUM, Alicante Institute of Ophthalmology, Alicante, Spain ‡Ophthalmology Unit, Albacete Medical School, Castilla La Mancha University, Albacete, Spain §Allergy Unit, Pio del Rio Hortega University Hospital, Valladolid, Spain.
authors.forename: Javier A
authors.initials: JA
authors.lastname: Montero
authors.forename: Jose M
authors.initials: JM
authors.lastname: Ruiz-Moreno
authors.forename: Maria Eugenia
authors.initials: ME
authors.lastname: Sanchis-Merino
authors.forename: Santiago
authors.initials: S
authors.lastname: Perez-Martin
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D057135:Wet Macular Degeneration / Q000188:drug therapy*
chemical_list: D000319:Adrenergic beta-Antagonists; D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized